Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Core Insights - Analysts project Travere Therapeutics (TVTX) will report a quarterly loss of $0.58 per share, a 50$73.44 million, reflecting a 63% increase from the same quarter last year [1] Earnings Estimates - Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 9.9%, indicating a reassessment by covering analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenue- Tiopronin products / Thiola' will reach $24.03 million, a decrease of 4.7$45.31 million, indicating a significant year-over-year increase of 208.3% [5] - 'Revenue- License and collaboration revenue' is expected to be $4.77 million, reflecting a decrease of 7.2% from the year-ago quarter [5] Stock Performance - Travere shares have increased by 24.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.7% [6] - With a Zacks Rank of 3 (Hold), TVTX is anticipated to closely follow overall market performance in the near term [6]